Business
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
FEATURED STORIES
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
It doesn’t matter how many times you have traversed Union Square; no one knows which way is north, or where The Westin is in relation to the Ritz Carlton. A Verizon outage brought that into focus on Wednesday.
Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Despite the loss of its COVID-19 antibody, REGEN-COV, earlier this year, Regeneron posted a positive first quarter driven primarily by sales of Dupixent and Eylea.
Moderna held its 2022 Q1 earnings call this morning announcing $6.1 billion in revenue and robust plans to roll out COVID-19 boosters this fall.
BioSpace sat down with Sven Kili, 2022 ISCT Annual Meeting co-chair, to preview the event, which will focus on 4 key subject areas including launch and commercialization of cell and gene therapies.
Over the past several years, The Lone Star State has been growing in significance as a life sciences hub. Now the industry is flocking to Hays County and its Innovation Corridor.
David Sabatini has withdrawn his name for consideration for a faculty post at New York University Langone Health.
Spero is reducing a huge chunk of its staff to minimize expenses and reallocate resources toward more promising projects in anticipation of the FDA’s decision on its NDA for tebipenem HBr.
Genesis Therapeutics and Eli Lilly have entered into a strategic collaboration to discover novel therapies utilizing Genesis’ AI platform.
Denali Therapeutics, Inc. has announced that dosing has begun for participants of a Phase II clinical trial that intends to evaluate the potential of SAR443820 (DNL788) in patients with amyotrophic lateral sclerosis (ALS).
Biogen announced the leadership change in its quarterly financial report. Michel Vounatsos plans to depart the company when a new CEO is found.
Teva announced that it had reached a deal with Lupin over Lupin’s Abbreviated New Drug Application (ANDA) for generic deutetrabenazine - an upcoming competitor to Hungtington’s drug Austedo.